140MEngageddaily users
600kAktivcontent creators
1MHoursof free content
Kostenlos registrieren
Kostenlos registrieren und verbessere dein Erlebnis
Create your own playlists.
Engage with the community.
Tailored video suggestions.
While the BioTime case was marked by controversy, it has also contributed to a greater awareness of the importance of integrity and accountability in the biotechnology sector.
In 2013, BioTime merged with a subsidiary of Ambit Biosciences, another biotechnology company. The merged entity, called BioTime, Inc., continued to develop and market various products, including those related to aging and regenerative medicine.
The BioTime controversy highlights the importance of regulatory compliance and transparency in the biotechnology industry. It also underscores the need for companies to prioritize scientific evidence and substantiation when making claims about their products.
While the BioTime case was marked by controversy, it has also contributed to a greater awareness of the importance of integrity and accountability in the biotechnology sector.
In 2013, BioTime merged with a subsidiary of Ambit Biosciences, another biotechnology company. The merged entity, called BioTime, Inc., continued to develop and market various products, including those related to aging and regenerative medicine.
The BioTime controversy highlights the importance of regulatory compliance and transparency in the biotechnology industry. It also underscores the need for companies to prioritize scientific evidence and substantiation when making claims about their products.